EN
0
Home > Products > Pharmaceutical R&D Materials > Heterocyclic Building Blocks > N-(3-CHLORO-4-(10,11-DIHYDRO-5H-BENZO[E]PYRROLO[1,2-A][1,4]DIAZEPINE-10-CARBONYL)PHENYL)-5-FLUORO-2-METHYLBENZAMIDE
N-(3-CHLORO-4-(10,11-DIHYDRO-5H-BENZO[E]PYRROLO[1,2-A][1,4]DIAZEPINE-10-CARBONYL)PHENYL)-5-FLUORO-2-METHYLBENZAMIDE structure, CAS 168079-32-1

N-(3-CHLORO-4-(10,11-DIHYDRO-5H-BENZO[E]PYRROLO[1,2-A][1,4]DIAZEPINE-10-CARBONYL)PHENYL)-5-FLUORO-2-METHYLBENZAMIDE

CAS Number168079-32-1

SynonymsWAY-VPA-985; VPA-985; lixivaptan; UNII-8F5X4B082E

Molecular FormulaC27H21ClFN3O2

Molecular Weight473.93

Purity≥96 (HPLC)%

Density1.3±0.1 g/cm3

Boiling Point626.5±55.0 °C at 760 mmHg

Melting Point

Flash Point

Appearancepowder

EINECS0

MSDSChineseEnglish

Symboltransportation

Signal WordWarning

Cat. No.: 2A-0160949 Purity: ≥96 (HPLC)%
Change View

Please Login or Create an Account to: See VlP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

Inquiry

Quality Control of [ 168079-32-1 ] Purity: ≥96 (HPLC)% SDS Specification MoL

COA NMR CNMR HPLC LC-MS
Chemical & Physical Properties
CAS Number168079-32-1
Catalog No.2A-0160949
Chinese Name利赛伐坦
SynonymsWAY-VPA-985; VPA-985; lixivaptan; UNII-8F5X4B082E
Molecular FormulaC27H21ClFN3O2
Molecular Weight473.93
Purity≥96 (HPLC)
Density1.3±0.1 g/cm3
Boiling Point626.5±55.0 °C at 760 mmHg
Appearancepowder
Storage Condition-20°C, sealed, dry
ApplicationLixivaptan (VPA-985, WAY-VPA 985) is an orally active, selective vasopressin receptor V2 antagonist with IC50 values ​​of 1.2 and 2.3 nM in humans and rats, respectively.
EINECS0
HTC0
UN(IATA)0
PubChem ID7980888
SMILESFc1cc(c(cc1)C)C(=O)Nc2cc(c(cc2)C(=O)N3Cc4[n](ccc4)Cc5c3cccc5)Cl
InChI1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
InChI KeyPPHTXRNHTVLQED-UHFFFAOYSA-N
NACRES CodeNA.77
UNSPSC51111800
Hazard Symbolstransportation
MSDSmsds/160949_1_168079_32_1.pdf
BioactivityLixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively. Related Catalog Signaling Pathways >> GPCR/G Protein >> Vasopressin Receptor Research Areas >> Cardiovascular Disease Target IC50: 1.2 nM (human V2), 2.3 nM (rat V2)[1] In Vitro Lixivaptan displays competitive antagonist activity at V2 receptors[1]. In Vivo In conscious dogs, water-loaded with 30 mL/kg (po) and arginine vasopressin (AVP)-treated (0.4 µg/kg in oil, sc), lixivaptan (1, 3, and 10 mg/kg po) increases Uvol over the AVP-treated vehicle group by 438, 1018, and 1133%, respectively, while Uosm decreases from 1222 mOsm/kg (water-loaded and AVP treated vehicle) to 307, 221, and 175 mOsm/kg, respectively. In homozygous Brattleboro rats lacking AVP, lixivaptan at 10 mg/kg po (i.e., 10 times the dose producing V2 antagonist activity) b.i.d. for 5 days, shows a sustained antagonist action without evidence of agonist effects. In a randomized double-blind placebo-controlled ascending single dose study, patients (deprived of fluids overnight before dosing) are dosed orally with 30, 75, or 150 mg of lixivaptan. All three doses increase urine flow and serum sodium concentrations and produced significant dose-related decreases in urinary osmolality[1]. Phase II clinical trials in patients with congestive heart failure, liver cirrhosis with ascites or syndrome of inappropriate antidiuretic hormone have demonstrated that lixivaptan increases water clearance without affecting renal sodium excretion or activating the neurohormonal system[2]. References [1]. Albright JD, et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem. 1998 Jul 2;41(14):2442-4. [2]. Ghali JK, et al. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. IDrugs. 2010 Nov;13(11):782-92. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Boiling Point 626.5±55.0 °C at 760 mmHg Molecular Formula C27H21ClFN3O2 Molecular Weight 473.926 Flash Point 332.7±31.5 °C Exact Mass 473.130646 PSA 57.83000 LogP 7.23 Vapour Pressure 0.0±1.8 mmHg at 25°C Index of Refraction 1.658 InChIKey PPHTXRNHTVLQED-UHFFFAOYSA-N SMILES Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1
Use ofLixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively. Properties Name N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide Synonym More Synonyms Lixivaptan Biological Activity Description Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively. Related Catalog Signaling Pathways >> GPCR/G Protein >> Vasopressin Receptor Research Areas >> Cardiovascular Disease IC50: 1.2 nM (human V2), 2.3 nM (rat V2)[1] In Vitro Lixivaptan displays competitive antagonist activity at V2 receptors[1]. References [1]. Albright JD, et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem. 1998 Jul 2;41(14):2442-4. [2]. Ghali JK, et al. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. IDrugs. 2010 Nov;13(11):782-92. Chemical & Physical Properties Exact Mass 473.130646 PSA 57.83000 Index of Refraction 1.658 InChIKey PPHTXRNHTVLQED-UHFFFAOYSA-N
Transport InfoShipping Name: UN
MSDS Transport InfoModule 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available
Related Products in Heterocyclic Building Blocks
N-(2-HYDRAZINYL-2-OXOETHYL)BENZO[C][1,2,5]THIADIAZOLE-4-SULFONAMIDE175203-26-62A-0160684
N-(2-METHYLBENZYL)-1-(TETRAHYDROFURAN-2-YL)METHANAMINE356531-12-92A-0160757
N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)-8-(METHYLSULFONAMIDO)DIBENZO[B,D]FURAN-1-CARBOXAMIDE778576-62-82A-0160801
N-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)PIPERIDINE-1-CARBOXAMIDE874299-01-12A-0160820
N-(3-(FURAN-2-YL)PHENYL)ACETAMIDE400745-80-42A-0160835
N-(3-FLUOROBENZYL)-1-(TETRAHYDROFURAN-2-YL)METHANAMINE510723-79-22A-0160984
N-(3-FLUOROPHENYL)THIOPHENE-2-CARBOXAMIDE136340-92-62A-0160992
N-(3-METHOXYBENZYL)-1-(TETRAHYDROFURAN-2-YL)METHANAMINE510723-82-72A-0161023
N-(3-METHYLBENZYL)-1-(TETRAHYDROFURAN-2-YL)METHANAMINE356530-65-92A-0161035
N-(4,7-DIHYDRO-4-OXO-1H-PYRROLO[2,3-D]PYRIMIDIN-2-YL)-2,2-DIMETHYLPROPANAMIDE137281-08-42A-0161055
Browse all Heterocyclic Building Blocks products »
Contact Us

Phone:

630-322-8886

630-322-8887

Email:

[email protected]

Office Locations:

Chicago, IL, USA

San Francisco, CA, USA